PubMed Journals Articles About "GSK1120212 Treatment Cancer" RSS

15:39 EST 22nd January 2019 | BioPortfolio

GSK1120212 Treatment Cancer PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest GSK1120212 Treatment Cancer articles that have been published worldwide.

More Information about "GSK1120212 Treatment Cancer" on BioPortfolio

We have published hundreds of GSK1120212 Treatment Cancer news stories on BioPortfolio along with dozens of GSK1120212 Treatment Cancer Clinical Trials and PubMed Articles about GSK1120212 Treatment Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GSK1120212 Treatment Cancer Companies in our database. You can also find out about relevant GSK1120212 Treatment Cancer Drugs and Medications on this site too.

Showing "GSK1120212 Treatment Cancer" PubMed Articles 1–25 of 39,000+

Higher Age Puts Lung-Cancer Patients at Risk for Not Receiving Anti-cancer Treatment.

We aimed to determine the demographic and epidemiologic variables that are associated with no treatment in lung cancer patients.

Second Malignancies Following Childhood Cancer Treatment in Germany From 1980 to 2014.

Because of improvements in cancer treatment, more than 80% of all children with cancer now survive at least five years from the time of diagnosis. As a result, late sequelae of cancer and its treatment have become more common, particularly second malignancies. We studied the current incidence of second malignancies among childhood cancer survivors in Germany.

The IASP classification of chronic pain for ICD-11: chronic cancer-related pain.

Worldwide, the prevalence of cancer is rising and so too is the number of patients who survive their cancer for many years thanks to the therapeutic successes of modern oncology. One of the most frequent and disabling symptoms of cancer is pain. In addition to the pain caused by the cancer, cancer treatment may also lead to chronic pain. Despite its importance, chronic cancer-related pain is not represented in the current International Classification of Diseases (ICD-10). This article describes the new clas...

Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.

Patients undergoing treatment for cancer are at increased risk of acute kidney injury (AKI). There are few data on AKI incidence and risk factors in the current era of cancer treatment.

Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study.

Patients with newly diagnosed lung cancer who have not yet begun treatment may already be experiencing major symptoms produced by their disease. Understanding the symptomatic effects of cancer treatment requires knowledge of pretreatment symptoms (both severity and interference with daily activities). We assessed pretreatment symptom severity, interference, and quality of life (QOL) in treatment-naïve patients with lung cancer and report factors that correlated with symptom severity.

Value and Values in Cancer Care. Assessing the Benefit of Treatment in Patients with Advanced Cancer.

In recent years, the term "value-based healthcare" has been increasingly used in debates about costs and outcomes of health interventions in cancer care. This paper distinguishes 2 meanings of the term "value" and explores the relevance of both meanings of the word for assessing the "value" of cancer drugs. At the focus of the analysis are value judgments which form an integral part of the assessment of benefit of cancer drugs. The review concludes with a reflection on individual competences and systemic fa...

Influence of the time interval from diagnosis to treatment on survival for early-stage liver cancer.

Liver cancer is the fifth most common cancer in men and the ninth most common cancer in women, and the WHO expects that there will be 1,341,344 cases in 2034 worldwide. Liver cancer also has the second-highest cancer death rate, accounting for 7% of all cancers. The study is going to explore the relationship between time interval from diagnosis to treatment and survival status of early-stage liver cancer patients.

Quality of diabetes care in breast, colorectal, and prostate cancer.

Overlooking other medical conditions during cancer treatment and follow-up could result in excess morbidity and mortality, thereby undermining gains associated with early detection and improved treatment of cancer. We compared the quality of care for diabetes patients subsequently diagnosed with breast, colorectal, or prostate cancer to matched, diabetic non-cancer controls.

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).

We determined if intermittent first-line treatment with paclitaxel plus bevacizumab was not inferior to continuous treatment in patients with HER2-negative, advanced breast cancer.

Developing a needs assessment questionnaire for women of reproductive age following breast cancer treatment: a cross-sectional pilot study in a Romanian sample.

Studies addressing the needs of cancer patients highlight the necessity to identify what types of informational and support needs are specific to women of reproductive age after primary treatment for breast cancer. We developed a questionnaire for evaluating informational and treatment decision, psychological and socio-familial needs in young breast cancer patients following treatment.

The capabilities and hope of the combination the new forms of personalized colon cancer treatment - immunotherapy and immune photodynamic therapy.

PDT can interfere with cytokine-mediated responses that play an important role in the processes of cancer progression, tumor angiogenesis and metastasis. Therefore, based on the identification of these cancer biomarkers, the therapy of combining various forms of treatment, including immunotherapy and PDT, may be a justified strategy for colorectal cancer treatment that focuses on individualized comprehensive therapy.

Palliative treatment of germ cell cancer.

Most patients with metastatic germ-cell cancer (GCC) can be cured by cisplatin-based combination chemotherapy. Yet, about 10-15% of metastatic GCC patients will eventually die of their disease. This narrative review focuses on treatment options when cure is no longer realistic.

The "sphere of care": A qualitative study of colorectal cancer patient and caregiver experiences of support within the cancer treatment setting.

Colorectal cancer is associated with considerable physical and psychosocial burden. Whilst social support is known to facilitate psychological adjustment to cancer, patients' and caregivers' experiences of social support within a treatment setting and their perceptions of the role of the treating team in providing this support is unknown. Specifically, there is a gap in the research that explores in detail who people affected by colorectal cancer consider to be supportive, and the function, timing and natur...

Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.

Various options for the pharmacological treatment of breakthrough cancer pain (BTcP) are available. International guidelines on BTcP treatment are not univocal. A tailored treatment should be based on the assessment of different variables such as BTcP characteristics, oral mucositis, chronic rhinitis and a patient's ability to take medication.

Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer.

Fatigue is one of the most common and disabling side effects of cancer and its treatment. Although research typically has focused on fatigue that occurs during and after treatment, patients may experience fatigue even before treatment onset. The current study was designed to identify biobehavioral risk factors associated with fatigue before adjuvant therapy in women with early-stage breast cancer.

Electrochemotherapy in the Treatment of Breast Cancer Metastasis to the Skin and Subcutaneous Tissue - Multicenter Experience.

Breast cancer is responsible for more than 50% of cutaneous metastases. One of the treatment options is electrochemotherapy (ECT). It is an effective method of local tumor ablation through the application of electroporation. The primary objective of the study was to demonstrate a response to the treatment in our group of patients.

KIF11 Functions as an Oncogene and Is Associated with Poor Outcomes from Breast Cancer.

The study aimed to search and identify genes that were differentially expressed in breast cancer, and their roles in cancer growth and progression.

Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.

Previous studies on the role of TP53 mutation in breast cancer treatment response and survival are contradictory and inconclusive, limited by the use of different endpoints to determine clinical significance and by small sample sizes that prohibit stratification by treatment.

An orthotopic non-small cell lung cancer model for image-guided small animal radiotherapy platforms.

Lung cancer is the deadliest cancer worldwide. To increase treatment potential for lung cancer, preclinical models that allow testing and follow up of clinically relevant treatment modalities are essential. Therefore, we developed a single-nodule-based orthotopic non-small cell lung cancer (NSCLC) tumor model which can be monitored using multimodal non-invasive imaging to select the optimal image-guided radiation treatment plan.

Using data linkage to report surgical treatment of breast cancer in Canada.

National population information about the surgical treatment rate for primary cancers, including breast cancer, has remained a significant data gap in Canada. This gap has implications for cancer care planning and evaluating health system performance. New linkages between the Canadian Cancer Registry and hospital discharge records were conducted by Statistics Canada in 2016. Using already existing, routinely collected health administrative data, these linkages allow viable reporting of surgical cancer treat...

Influence of dental treatment in place on quality of life in oral cancer patients undergoing chemoradiotherapy.

This study aims to assess, in the population of patients with oral cancer treatment, the influence on the quality of life of two protocols of dental treatment: not ruled hospital treatment versus ruled hospital treatment. Matrial and Methods: A quasi-experimental approach justified on ethical grounds was used. A total of 41 patients were included in the control group (not ruled treatment outpatient health center) and 40 in the experimental group (ruled hospital treatment). A total of 14 questions to both gr...

Molecular targeted therapy: treating cancer with specificity.

Molecular targeted therapies are revolutionized therapeutics which interfere with specific molecules to block cancer growth, progression and metastasis. Many molecular targeted therapies approved by the Food and Drug Administration (FDA), have demonstrated remarkable clinical success in the treatment of a myriad of cancer types including breast, leukemia, colorectal, lung, and ovarian cancers. This review provides an update on the different types of molecular targeted therapies used in the treatment of canc...

Understanding the Benefits of Acupuncture Treatment for Cancer Pain Management.

This article summarizes the current evidence regarding the use of acupuncture for pain management in cancer patients. It includes a description of how acupuncture is thought to work and what the intervention entails, data on acupuncture for managing pain caused by cancer or by cancer treatment (radiation, chemotherapy, endocrine therapy), how acupuncture is practiced in the US medical system, discussion of safety issues, and practical tips on how to integrate acupuncture into cancer care.

Cancer Drug Toxicity: Moving from Patient to Survivor.

Millions of individuals worldwide are living with cancer and have remained disease-free for more than 5 years. These individuals are considered to be cancer survivors. The advent of new targeted therapies and personalized treatment modalities have contributed to this increased survivorship. Additionally, earlier diagnosis and detection of cancer, greater access to preventive screenings, and greater focus on cancer pharmaceutical safety have all been contributed to increasing longevity. Of note, all cancer t...

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study.

Treatment targeting immune checkpoint with PD-1/PD-L1 inhibitors has demonstrated efficacy and tolerability in the treatment of metastatic urothelial carcinoma (mUC). We investigated the efficacy and safety of atezolizumab in mUC patients who failed platinum-based chemotherapy.

Quick Search